The biotech industry faces a complex landscape defined by record-breaking secondary offerings, shifting investor appetites, and significant regulatory volatility. While strong clinical data continues to drive capital inflows, the rapid pace of M&A—highlighted by the acquisition of Candid Therapeutics—underscores the strategic value of assets sourced from China. Regulatory oversight remains a point of contention, as leadership changes at the FDA and the controversial commissioner's voucher program create uncertainty for drug developers. Meanwhile, the industry is grappling with evolving standards for clinical evidence, particularly regarding the acceptance of neurofilament biomarkers in neurodegenerative trials. Despite robust innovation, commercial-stage companies struggle to maintain investor interest compared to developmental-stage firms, reflecting a broader market preference for high-upside, pipeline-driven opportunities. These dynamics necessitate a more disciplined approach to capital deployment and a clearer, more stable regulatory framework to sustain long-term sector health.
Sign in to continue reading, translating and more.
Continue
